Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.64 |
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.57 |
| ▸ | SQLE | Q14534 | 6/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | FNTA | P49354 | 2/20 | 0.52 |
| ▸ | FNTB | P49356 | 2/20 | 0.52 |
| ▸ | GGPS1 | O95749 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7757953 | 1.00 | KMT2A (0.64) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL530927 | 1.00 | KMT2A (0.64) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL954111 | 0.96 | KMT2A (0.56) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL954112 | 0.96 | KMT2A (0.56) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| Squalene SCHEMBL27987791 | 0.87 | KMT2A (0.85) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL11436605 | 0.83 | BTN3A1 (0.44) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL11436601 | 0.83 | BTN3A1 (0.44) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL8702915 | 0.82 | SQLE (0.43) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL8702913 | 0.82 | SQLE (0.43) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL23802597 | 0.79 | KMT2A (1.00) | KMT2AMAPTMEN1CYP3A4ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6110933-A | AN ENZYME INHIBITOR TREATING PANCREATITIS, HEPATITIS, CHRONIC RENAL FAILURE, ENDOTOXIN SHOCK, GRAM-NEGATIVE SEPTIC SHOCK, ARTHRITIS, RESPIRATORY DISEASE, HEART DISEASE, ALLERGIC DISEASE, THROMBOSIS, ARTERIOSCLEROSIS, PAIN | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-08-29 | — | — | US | claimed |
| US-9901565-B2 | Membrane fusion inhibitor | PROTECTEA, LTD. (JP) | 2018-02-27 | — | — | US | disclosed |
| US-9801850-B2 | Antibacterial agent | OSAKA UNIVERSITY (JP) | 2017-10-31 | — | — | US | disclosed |
| US-20150111961-A1 | MEMBRANE FUSION INHIBITOR | PROTECTEA, LTD. (JP) | 2015-04-23 | — | — | US | disclosed |
| EP-2460405-B1 | EPIGALLOCATECHIN GALLATE DERIVATIVE AS ANTIBACTERIAL AGENT | UNIV OSAKA (JP) | 2015-03-18 | — | — | EP | disclosed |
| US-8952055-B2 | Membrane fusion inhibitor | PROTECTEA, LTD. (JP) | 2015-02-10 | — | — | US | disclosed |
| EP-2460405-A1 | ANTIBACTERIAL AGENT | Osaka University (JP) | 2012-06-06 | — | — | EP | disclosed |
| US-20120136049-A1 | ANTIBACTERIAL AGENT | OSAKA UNIVERSITY (JP) | 2012-05-31 | — | — | US | disclosed |
| EP-1854877-B1 | Process for the deacylation of cyclic lipopeptides | ASTELLAS PHARMA INC (JP) | 2012-02-08 | — | — | EP | disclosed |
| US-20110003889-A1 | MEMBRANE FUSION INHIBITOR | KAIHATSU, Kunihiro (JP) | 2011-01-06 | — | — | US | disclosed |
| US-5463181-A | Farnesyl: protein transferase inhibitors as anticancer agents | MERRELL DOW PHARMACEUTICALS INC. (US) | 1995-10-31 | — | — | US | disclosed |
| WO-1995019959-A1 | AMINO ACID DERIVATIVES AND THEIR USE AS PHOSPHOLIPASE A2 INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1995-07-27 | — | — | WO | disclosed |
| EP-0644199-A1 | Cyclic antimicrobial peptides and preparation thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1995-03-22 | — | — | EP | disclosed |
| US-5376634-A | Microbiocides | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1994-12-27 | — | — | US | disclosed |
| WO-1994019357-A1 | FARNESYL:PROTEIN TRANSFERASE INHIBITORS AS ANTICANCER AGENTS | MERRELL DOW PHARMACEUTICALS INC. (US) | 1994-09-01 | — | — | WO | disclosed |
| EP-0332143-B1 | 11beta,17alpha,21-trihydroxy-1,4-pregnadiene-3,20-dione 21-[(E,E)-3,7,11-trimethyl-2,6,10-dodecatrienoate] | KURARAY CO (JP) | 1994-03-16 | — | — | EP | disclosed |
| US-5278156-A | Steroids | KURARAY CO., LTD. (JP) | 1994-01-11 | — | — | US | disclosed |
| EP-0462531-A2 | Cyclic polypeptide with antibiotic activity, process for its preparation and pure culture of a Coelomycetes strain | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1991-12-27 | — | — | EP | disclosed |
| US-5015746-A | Esterification of prednisolone with 3,7,11-trimethyl-2,6,10-dodecatrienoic acid in the presence of disubstituted aminopyridines and a condensing agents | KURARAY CO., LTD. (JP) | 1991-05-14 | — | — | US | disclosed |
| EP-0332143-A1 | 11beta,17alpha,21-trihydroxy-1,4-pregnadiene-3,20-dione 21-[(E,E)-3,7,11-trimethyl-2,6,10-dodecatrienoate] | KURARAY CO., LTD. (JP) | 1989-09-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120136049-A1 | ANTIBACTERIAL AGENT | TEAD4, ELOVL6, TEAD1 | KMT2A 1258/4885MAPT 4224/4885MEN1 4331/4885 |
| US-20150111961-A1 | MEMBRANE FUSION INHIBITOR | FLOT1, NSF, VAMP7 | KMT2A 2118/4885MAPT 3717/4885MEN1 2941/4885 |
| US-20110003889-A1 | MEMBRANE FUSION INHIBITOR | FLOT1, NSF, VAMP7 | KMT2A 2118/4885MAPT 3717/4885MEN1 2941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.